Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna Announces Proposed Follow-On Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 5, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the commencement of a proposed underwritten registered public offering of 6,150,000 shares of...
View HTML
Toggle Summary Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria
Initial 6-Week Data in PHYOX Phase 1 Trial Show Significant and Sustained Reduction in Urinary Oxalate Levels Following Single-Dose Administration in Adults with PH1 and PH2 A Detailed Data Readout of the PHYOX Trial is Anticipated in Q4 2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep....
View HTML
Toggle Summary Dicerna to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 29, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will participate in...
View HTML
Toggle Summary Dicerna Strengthens Board of Directors with Two New Appointments
Industry Veterans J. Kevin Buchi and Cynthia Smith Add Key Industry and Commercial Operations Expertise CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 16, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today...
View HTML
Toggle Summary Dicerna Reports Second Quarter 2018 Financial and Operating Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the...
View HTML
Toggle Summary Dicerna to Report Second Quarter 2018 Financial Results and Host Conference Call on August 8, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2018 financial results after market close on...
View HTML
Toggle Summary Dicerna Receives Recommendation from EMA Committee to Designate DCR-PHXC an Orphan Medicinal Product for the Treatment of Primary Hyperoxaluria (PH) in the EU
COMP Opinion Cites Encouraging Preclinical Data and Chronically Debilitating and Life-threatening Nature of PH CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 11, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics,...
View HTML
Toggle Summary Dicerna Set to Join the Russell 3000® and Russell 2000® Indexes
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 19, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company is set to join the broad-market Russell 3000 ® Index and the small-cap Russell...
View HTML
Toggle Summary Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial
FDA Grants Orphan Drug Designation for DCR-PHXC for the Treatment of Primary Hyperoxaluria CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 30, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that...
View HTML
Toggle Summary Dicerna to Present at the Jefferies 2018 Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will provide a...
View HTML